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Abstract
A decade of research in Switzerland, The Netherlands, Germany, and Spain now constitutes a
massive body of work supporting the use of heroin treatment for the most difficult patients
addicted to opiates. These trials concur on this method's safety and efficacy and are now serving
as a prelude to the institution of heroin treatment in clinical practice throughout Europe.
While the different sampling and research protocols for heroin treatment in these studies were
important to the academic claims about specific results and conclusions that could be drawn from
each study, the overall outcomes were quite clear – and uniformly positive. They all find that the
use of prescribed pharmaceutical heroin does exactly what it is intended to do: it reaches a
treatment refractory group of addicts by engaging them in a positive healthcare relationship with a
physician, it reduces their criminal activity, improves their health status, and increases their social
tenure through more stable housing, employment, and contact with family.
The Canadian trial (NAOMI), now underway for over a year, but not yet completed, now faces a
dilemma about what to do with its patients who have successfully completed 12 months of heroin
and must be withdrawn from heroin and transferred to other treatments in accordance with the
research protocol approved by Government of Canada, federal granting body and host institutions.
The problem is that the principal criterion for acceptance to NAOMI was their history of repeated
failure in these very same treatment programs to which they will now be referred.
The existence of the results from abroad (some of which were not yet available when NAOMI was
designed and initiated) now raises a very important question for Canada: is it ethical to continue to
prohibit the medical use of heroin treatment that has already been shown to be feasible and
effective in numerous medical studies throughout the world? And while this is being worked out,
is it acceptable to require patients who have been successfully treated with heroin in Canada, to
be forced to move back to less effective treatments (treatments that failed to be efficacious in the
past)?
This essay discusses this dilemma and places it in the broader context of ethics, science, and health
policy. It makes the case for continuation of the current successful patients in heroin treatment and
the institution of heroin treatment to all Canadian patients living with active addictions who qualify.
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"laws and institutions must go hand in hand with the progress
of the human mind. As that becomes more developed, more
enlightened, as new discoveries are made, new truths discov-
ered and manners and opinions change, with the change of cir-
cumstances, institutions must advance also to keep pace with
the times. We might as well require a man to wear still the coat
which fitted him when a boy..."
Thomas Jefferson[1]
The Portland Hotel Society (PHS) is a non- profit social,
health, and housing agency based in Vancouver's Down-
town Eastside that has been active in providing services
for people with active addictions for 15 years. The PHS
operates a community based medical clinic treating this
population with methadone maintenance, residential
programs, and other approaches appropriate to people
living with chronic heroin addiction. Despite the best
intentions of these programs and the many fine clinicians
practicing traditional addiction medicine, many in this
population return again and again to heroin injecting –
even in the face of the very real risks of AIDS, Hepatitis,
overdose and the inevitable arrests and imprisonments
associated with the illegal activities needed to get money
for their habit. While many heroin users are eventually
able to manage their addiction, some of the most troubled
and persistent ones continue a downward slide and their
continued use of heroin brings disastrous consequences.
So obvious is this aspect of the heroin problem that many
have said (including some police): "why not just give
them the drug they seek – heroin?" Why not indeed?
On 29 January 2001, PHS, applied to the Federal Govern-
ment of Canada for legal permission to prescribe heroin
in Vancouver. Heroin prescription for the treatment of
pain has been allowed in Canada since 1985 [2] and has
been in the UK and many other countries for decades
before that. Heroin maintenance of addicts has been used
in clinical practice in the UK since 1926 [3]. Today, there
are approximately 400 individuals receiving heroin in
England as part of addiction treatment [4]. But Canadian
federal regulators held that heroin treatment of addiction
was a new use of the drug and that a Canadian research
study would have to be done before any agreement to
allow the use of heroin in Canada to treat heroin addic-
tion. Assumedly this study was to be done for the purpose
of assessing heroin's suitability for institution as a routine
treatment in Canada, i.e. a first step towards making it
routinely available for those heroin addicts who fit a pro-
file indicating that it would be helpful for them in the
treatment of their addiction.
Similar to the care of many cancer patients, the heroin
treatment of opiate addiction isn't necessarily curative
(i.e. having a goal of eventual abstinence from the drug);
but is the best treatment option that the clinician can
offer. In some of the saddest cases, it is essentially a palli-
ative intervention aimed at reducing pain and suffering.
But just as people living with cancer cannot simply enter
the local pharmacy and purchase restricted drugs used in
chemotherapy by medical oncologists in the treatment of
cancer, so too, no one envisaged intractable heroin
addicts going to the local pharmacy to purchase heroin. As
patients in such a program, heroin addicts would need to
be properly assessed by a qualified clinician and be able
to receive the otherwise restricted treatment under vigilant
medical supervision. And in order to properly supervise
this form of treatment, Canadian practitioners would
have to learn how to do it first hand. The start of this proc-
ess has been the North American Opiate Medication Initi-
ative (NAOMI).
The research team, led by principal investigator Dr. Martin
Schechter, an epidemiologist and Director of the Centre
for Health Evaluation and Outcomes Sciences (CHEOS),
established Canada's leadership position in North Amer-
ica with respect to innovative addiction research. Struc-
tured from the outset as a rigorous randomized clinical
trial (RCT) with very careful attention to research design
and the selection of the study population and controls,
the study was expensive by research standards, over CA $
8,100,000 for 5 years, and one of the largest grants ever
awarded by the Canadian Institute for Health Research
(CIHR). However, viewed relative to the costs of illicit
drug addiction to individuals, families and society (esti-
mated at $48 per capita 1.4 billion Canadian dollars per
year) NAOMI could prove to be a real bargain. [5]
The plan for the NAOMI was to recruit 157 experimental
participants and an equal number of controls from three
Canadian cities: Vancouver, Montreal and Toronto.
Toronto later left the study and Vancouver and Montreal
increased their study populations. As in other trials, the
experimental group would receive pharmaceutical heroin
(for 12 months) while the control group would receive
methadone [6]. After nearly a decade of careful planning
along with immense effort at the regulatory and funding
level, the NAOMI began admission of its first patients in
March 2005.
Importantly, even if the study showed positive outcomes
for its participants no provision was made for continuing
heroin for the study subjects after the 12-month heroin
treatment phase of the experiment. This is not to say that
the patients on heroin would be abandoned after one
year. Under the study protocol, researchers planned to
switch those subjects into methadone maintenance pro-
grams or other treatments of their choice. Recall that these
same subjects were selected for NAOMI exactly because
they had repeatedly failed at methadone treatment (orHarm Reduction Journal 2006, 3:16 http://www.harmreductionjournal.com/content/3/1/16
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other treatment programs) in which they had not suc-
ceeded – including repeated attempts at abstinence in tra-
ditional treatment programs [6]. The ethical review
boards at the three sponsoring institutions, the University
of British Columbia, Toronto Centre for Addictions and
Mental Health, and Universite de Montreal approved the
study and its plans to transition the experimental group
into the very same set of treatments conditions that had
repeatedly been shown not to benefit them, regardless of
the experimental results [6]. Thus while the NAOMI might
help to establish a new standard of care and, hopefully, of
caring for people living with active heroin addiction, the
lack of an ethically sound pragmatic strategy for continu-
ing heroin prescription if and when justified (based on all
the available research evidence) was a worry from the out-
set [7].
The investigators for the NAOMI were trailblazers explor-
ing new territory within the evolving framework of Cana-
dian drug treatment policies based on harm reduction
who were moving forward in the only way available
within the regulatory framework. They could neither pre-
sume to know the results of their experiment before the
science was completed, nor like previous studies in Swit-
zerland and the Netherlands could they presume that the
regulatory body would grant either an extension or expan-
sion of the research exemption allowing heroin treatment
for a time-limited period to a small group of addicted per-
sons after the trial period. To insist that Canadian health
authorities do so might have likely resulted in refusal of
funding and the necessary authorization to complete the
research.
Despite these complicated and potentially compromising
circumstances, the researchers directing NAOMI did not
blink as they undertook the political challenge to employ
science to show Canadians a way out of the addiction wil-
derness–in the classic framework of rigorous clinical
research. As public health and medical pioneers, they
agreed to draw on their symbolic capital and accumulated
prestige (see [8]) of their medical positions to discover the
scientific answers that were required to build both the sci-
entific and the cultural railway towards formal considera-
tion of the institution of heroin treatment in Canada.
The NAOMI's formal task was to answer specific research
questions about the feasibility, operational details and
procedures, and a set of important clinical outcomes of
heroin provision under medical auspices. But, from the
outset, this research initiative was also implicitly and
explicitly charged with the responsibility of helping to
develop a medical solution to one of the most vexing
problems facing Canada and many other nations, i.e. how
to deal effectively with the persistence of illicit heroin
injecting. Just as the problem was not a new one, there
were also precedents to draw upon for its solution. Several
other countries had gone down the same path of conduct-
ing careful experimental studies of heroin maintenance as
a first step to instituting it as an important treatment
option for the most refractory cases. What had they
learned? How might Canada benefit from the results of
these studies and experiences of these other societies as it
strove to add another layer of competency to deal with its
own heroin problems?
NAOMI and her sisters
There have been several carefully controlled trials of her-
oin maintenance that came before the NAOMI including
those performed in Switzerland (from 1995) the Nether-
lands (2000) and Germany (2002). These studies of her-
oin treatment varied with respect to the details of the
research protocol and inclusion criteria for subjects (and
accordingly each measures somewhat different outcomes
in different ways). But each of the European trials was a
test of the same basic proposition – could heroin be used
in medical practice to engage a target group previously not
reached or failed in a clinical relationship? And could it
reduce biological, social and personal risks of injecting
illegal drugs while reducing or eliminating crime by neces-
sity and survival sex trade work for active heroin users?
There are benefits to studying the use of a drug in different
settings and the NAOMI was not an exact re-run of previ-
ous trials. The NAOMI's particular clinical criteria and
protocol were adjusted for the Vancouver and Montreal
population: the subjects were of course all chronic heroin
users – and over 40% with HIV. They were all individuals
who had failed in many other attempts to bring their dan-
gerous and costly addiction under some control. The
study focused on this local sample as representatives of
the hardest cases of a much larger population (between
60,000 and 90,000 in Canada according to CIHR with
some estimates as high as 125,000) desperately in need of
new and more effective models of care[6,9].
The intravenous drug using population in Vancouver
includes both those addicted to heroin as well as those
addicted to cocaine and other stimulants. For instance,
close to 5000 individuals registered to utilize Vancouver's
supervised injection facility (SIF). Of the injections taking
place at the SIF, approximately 46 % are heroin, 37 %
cocaine [10]. Those opposed to harm minimization pub-
lic health approaches, sometimes make the argument that
Vancouver's addicts are substantively different in terms of
the substances they inject in their bodies, and the impen-
etrability of their addiction, and that this somehow justi-
fies a more guarded approach to innovations in addiction
medicine. Addiction is by its very nature challenging, in
all jurisdictions, and Canada does not have the market
cornered on the hardest to treat of those living with addic-Harm Reduction Journal 2006, 3:16 http://www.harmreductionjournal.com/content/3/1/16
Page 4 of 14
(page number not for citation purposes)
tions. There are opiate, stimulant and polydrug injectors
in many countries including the Netherlands [11], Swit-
zerland [12], Australia [13], Spain [14], the United King-
dom [15], as well as Germany, Italy and Ireland [16].
Further, in addition to the European trials, there was
nearly a century of clinical practice and experience in the
UK where physicians prescribed heroin for both pain
management and addiction in routine practice. This work
in the UK was not initially set up as a study, but was a
repository of decades of practical clinical experience with
heroin treatment for the UK's general medical practition-
ers, who, despite some restrictions always had the legal
right to exercise their clinical judgment with respect to
prescription of heroin. Heroin prescription occurs in a
wide variety of clinical settings in the UK (in several areas
of England as well as Scotland and Wales) there have also
been four previous studies of heroin prescription – in the
1970's, 1980's, 1990's, and 2001 [17] – and another is
underway now. This fundamental clinical work in the UK
shows that it is feasible to maintain some addicts on med-
ically prescribed heroin, even for decades, and still sets
important precedents for understanding the regulation of
heroin treatment in specialty addiction medicine practice.
But what did the rigorous research from other countries
show that could guide Canadian research and policy deci-
sions?
Switzerland
The Swiss were the first to show these effects through a
careful evaluation of prescribed heroin for over 1,000 of
the countries most refractory, long-term heroin addicts –
targeting the most difficult of individuals who have had
long-term difficulties with substance misuse and repeated
failures with traditional abstinence based approaches to
treatment. The Swiss studies showed unequivocally that
prescribing heroin produces substantial declines both in
illicit drug use and in criminal activity for this most prob-
lematic group. In addition, they provided clear evidence
of improved social reintegration, i.e. better housing, more
gainful employment, fewer drug associates and more con-
tact with previously estranged families and friends. Here
are some of details:
• Fitness for work improved considerably: permanent employ-
ment more than doubled (from 14 to 32%), unemployment fell
by more than half (44 to 20%)
• The patients' housing situation rapidly improved and stabi-
lized (there was in particular no homelessness)
• There was no fatal overdose due to prescribed substances
• No notable disturbances in local neighborhoods
• Significant economic benefit in terms of savings per patient-
day (relating to savings in criminal investigations and prison
days, followed by improvements in the state of health of the par-
ticipants)
• There was a marked decrease in shoplifting (35% to 16.1%),
breaking and entering (6.9 % to 0.0%), drug dealing and han-
dling stolen goods (13.1% to 3.9%), sale of hashish (26.3% to
12.5%), sale of hard drugs (46.9% to 8.2%) based on inter-
views at time of admission and after 12 months of treatment
• Overall, offences dropped by 68%: Notably, this drop is not
limited to short periods of time. The data from the Swiss study
shows that this drop remained stable after 24 months of treat-
ment. According to the Central Criminal Register, the number
of convictions dropped by 80% [18]
The Swiss approach to heroin treatment has been criti-
cized for being a program initiative rather than a rand-
omized trial. But the RCT is NOT the only means to
determine efficacy of new treatment strategies–indeed in
public health programs it is rarely even an option. The
successful introduction of methadone treatment occurred
without one, likewise the widespread use of penicillin fol-
lowing World War II.
The Swiss health authorities desired to move ahead
quickly with a heroin project that was as much demon-
stration and proof of principal as it was research per se. But
many of methodological concerns associated with their
approach were addressed (in advance) by the Swiss inves-
tigators, who went to great lengths to be conservative in
their methods and cautious in the conclusions they drew
from their results [19]. All the limitations of the study
design were well recognized and repeatedly addressed by
the meticulous Swiss investigators and in no way dimin-
ished the significance of their landmark study that
revealed that alternatives to methadone maintenance can
attract and retain addicts for whom methadone has
proved unsatisfactory [20,21]. The Swiss study was a
response to an epidemic – its heroin injectors had the
highest rate of HIV infection in Europe. Similarly, if a bird
flu pandemic were to occur, governments would not uti-
lize a RCT approach to test available public health inter-
vention strategies. The Swiss trial highlighted the positive
effects supporting a need to change policy and practice –
that's why they undertook it in the first place – and the fact
that its outcomes led directly to policy changes instituting
heroin treatment in Switzerland, was the whole point of
the enterprise, not a felicitous fringe benefit.
The fundamental premise of all narcotic maintenance is
that, for many patients addicted to opiates, the use of any
one of a number of substitutes produces health and psy-
chosocial results far superior to illicit street use or drugHarm Reduction Journal 2006, 3:16 http://www.harmreductionjournal.com/content/3/1/16
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free treatment. Drug abstinence was never the goal for the
Swiss patients, their doctors, or the Swiss Federal Office of
Public Health. The original intent of the study was to
improve retention of the patients in care, show improve-
ments in the clinical course of their addiction (i.e. reduced
illicit drug use and high risk injecting), and specific gains
in the social outcomes associated with a diminution in the
use of illegal drugs.
The outcomes from this study that account for its public
acceptance in a national referendum and the Swiss Federal
Health Department's decision to extend and expand the
program by over 50%, and for a half dozen other nations
to express interest in replicating the Swiss work. The objec-
tive of reducing AIDS risk among the Swiss population
was paramount to thinking about the use of research such
as this in the context of responsible leadership in public
health policy and is highly pertinent to the situation in
Canada.
Furthermore, re-enforcing the success of this strategic use
of research to inform both Swiss policy and larger con-
cepts of the scope of professional practice in addiction
medicine, even the preliminary Swiss results that were
decisive in persuading Dutch public health officials to ini-
tiate their own randomized study of heroin prescription
in Amsterdam and Rotterdam (for 750 participants), and
formed the basis of support for conducting similar pro-
grams as randomized controlled trials in Germany and in
Canada.
The Netherlands
The Dutch Heroin Maintenance Study was considered the
most rigorous study to date (it was an RCT) and its results
are fully available today. [22] Again these studies showed
that it was feasible to conduct a program that made heroin
medically available (for a 12 month trial period) to a
group of hard core addicts with multiple prior failures in
treatment. It also produced very positive results:
Adherence was excellent with 12 month outcome data available
for 94% of the randomized participants. With intention to treat
analysis, 12 month treatment with heroin plus methadone was
significantly more effective than treatment with methadone
alone in the trial of inhalable heroin (response rate 49.7% v
26.9%; difference 22.8%, 95% confidence interval 11.0% to
34.6%) and in the trial of injectable heroin (55.5% v 31.2%;
difference 24.3%, 9.6% to 39.0%)." [22]
But when the Dutch trial was ended and patients had to
stop the prescribed heroin and switch to methadone,
many reverted to heroin use and there were serious
adverse consequences for the addicts:
Discontinuation of the co-prescribed heroin resulted in a rapid
deterioration in 82% (94/115) of those who responded to the
co-prescribed heroin. The incidence of serious adverse events
was similar across treatment conditions. Conclusions were that
the supervised co-prescription of heroin is feasible, more effec-
tive, and probably as safe as methadone alone in reducing the
many physical, mental, and social problems of treatment resist-
ant heroin addicts." [22]
We will return to a discussion (in a later section of this
paper) of this crucial problem in all heroin research – i.e.
how to terminate the study when it is successful.
Germany
In Germany, approximately 35,000 to 40,000 heroin
addicts are in methadone treatment and about 35,000 are
not in any treatment [23]. The heroin study was a multi-
site trial in the cities of Bonn, Karsruhe, Koln, Hannover,
Frankfurt, Munchen and Hamburg. It is, like NAOMI, a
randomized control study that focuses on two target
groups: those heroin addicts presently enrolled in metha-
done maintenance that have not made significant gains in
treatment and those that are not yet in medical care but
require it due to their health status or life circumstance.
The main purpose of the study was to compare injectable
heroin to oral methadone with respect to treatment out-
comes in health, level of illicit drug use, crime, treatment
retention, disengagement from drug community, employ-
ment, social connection, housing situation and ability to
reach a difficult target group [24]. The total number of
participants in the study was 1,120 with 560 in the meth-
adone group and 560 in the untreated group. The first par-
ticipant was enrolled in March 2002 in a randomized
control trial to examine clinical efficacy of heroin in a
structured treatment setting as well as its impact on crime,
healthcare, cognitive-motor and neuropsychological
functioning [25]. A cost benefit analysis and evaluation of
the effects of two psychosocial interventions (motiva-
tional interviewing and addiction counseling) was also a
part of the trial. The pharmacological component of the
study was designed for 24 months with the entire study
taking 36 months.
The results were "unequivocally positive" was the conclu-
sion reached by Federal authorities and those of all seven
participating cities where illegal drug use was reduced,
health status improved, and there was better social inte-
gration and less criminality [26]. In light of these results,
the continuation of heroin treatment (as clinical practice
in Frankfurt) was approved by a large majority of the
Frankfurt City Council ("Stadtparlament"). The approval
of heroin as prescribed medication for all of Germany is
expected by June 2006. Based on the favorable results,
prescribable medication for the treatment of addiction,Harm Reduction Journal 2006, 3:16 http://www.harmreductionjournal.com/content/3/1/16
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heroin treatment for addiction as part of standard medical
practice has been recommended by the drug police coor-
dinator for Germany, Caspers-Merk [27].
Spain
With approximately 150,000 people living with serious
and persistent heroin addiction, three autonomous
regions of Spain (Andalusia, Catalunya and Basque
County) took the lead in convincing the Federal govern-
ment to provide the legal framework to allow clinical tri-
als of heroin prescription in 2001 [28,29]. From the
inception of the research, the trial's researchers publicly
disputed the Federal government's criteria that the
patients would have heroin withheld at the end of the
trial. Instead, the health authorities from the autonomous
regions and the principal investigators took the firm posi-
tion that it was medically unethical and inhumane to cut
patients off clinically prescribed heroin once the research
protocol was completed [30,31].
While the Basques have not yet been successful in obtain-
ing final approval for their proposed research trial from
the federal government of Spain, both Catalunya and
Andulusia have completed trials examining the adminis-
tration of heroin for addiction [28]. The Catalonian
research compared oral methadone therapy to oral heroin
therapy while the Audalusia randomized trial compared
intravenous heroin to oral methadone as medical treat-
ments for marginalized people addicted to heroin that
had not been successful in other treatments [32,33]. A
peer-to-peer recruitment strategy was employed as a strat-
egy for enhancing the researchers ability to reach the target
group.
Those prescribed heroin in the experimental group made
more gains than the control group receiving methadone
with respect to health and also demonstrated a corre-
sponding decrease in criminal activity, illicit heroin and
cocaine use, drug related problems and risk behaviors that
might lead to HIV infection [28]. The Andalusia research
took place between February 2003 and November 2004
and the results are presently being evaluated by the Span-
ish Drug Agency. The full results of the trial are due to be
published shortly [34].
Lessons learned
While these sampling and research protocol differences
were important to the academic claims about specific
results and the general conclusions that could be drawn
from each study, the overall outcomes were quite clear –
and uniformly positive. The cumulative international
research and the massive body of work to date all point to
the finding that the use of prescribed pharmaceutical her-
oin does exactly what it is intended to do–to reach a
nearly unreachable group of people by engaging them in
a healthcare relationship with a physician; reduce their
criminal activity; improve their health markedly; and
increases their social tenure in terms of homelessness and
employment.
While there are some differences, all of these studies and
their objectives, especially Germany's heroin project, are
very similar to NAOMI in several important ways – the
treatment population, sampling criteria, and research
designs that compare heroin to other treatment options.
The study objectives of these trials all closely parallel those
of the Canadian trial – to assess the suitability of pre-
scribed heroin for addiction treatment. And all the heroin
maintenance trials target difficult to treat, socially margin-
alized and unwell individuals living with serious and per-
sistent addictions. The unique characteristics of each
locality is not a justification for repeating randomized
control trials perpetually when the clear and obvious
beneficence of a medical treatment has been shown across
scores of settings. This would not be so easily justifiable in
other medical trials such as in the instance of cancer.
The existence of their results now raises a very important
question for Canada. Is it ethical to continue to prohibit
the medical use of a treatment that has already been
shown to be feasible and effective in numerous well con-
trolled scientific studies with similar populations of her-
oin users seen in a wide range of clinical settings similar
to what is available in Canada?
Canada at the cross roads: evidence and ethics
A decision point is about to be reached for the use of her-
oin treatment in Canada. This is precipitated by the loom-
ing expiration of the 12-month trial period built into
NAOMI, where a few dozen individuals are already receiv-
ing heroin treatment. According to the research protocol,
those patients who have been maintained under the
experimental regime must leave it after 12 months. A
growing number are scheduled to have heroin treatment
withdrawn within the next few months. This is not an aca-
demic issue. In light of the evidence of feasibility of oper-
ating the program safely already available from NAOMI,
and all the other trials, is it ethical to continue on the
present course? Do we really want to say that in Canada
patients who are doing well in a medical study can only
continue to have access to life saving treatment (which has
been shown repeatedly to be efficacious elsewhere)
through their continued participation in time constrained
research trial?
We know that some patients in heroin treatment use it as
a pathway to reducing or stopping their heroin use alto-
gether. In several of the European studies, some individu-
als chose to switch to methadone (usually in combination
with program heroin) while still on the trial. Using suffi-Harm Reduction Journal 2006, 3:16 http://www.harmreductionjournal.com/content/3/1/16
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cient doses, they generally do well (at least in terms of
staying in treatment and not relapsing to heroin). Some
even went into abstinence treatment in Switzerland. But
in the Netherlands, most did not want methadone and it
is likely that will hold true in NAOMI as well. It is note-
worthy that in the Swiss trials and often in UK practice,
once individuals in heroin treatment stabilize their lives,
they often prefer the less onerous program of methadone
with weekly or even monthly visits to clinic, rather than
thrice daily for heroin. This demanding regimen offers lit-
tle chance for a normal life, but is still better than having
to engage in risky activities such as crime or sex trade to
gain enough income for daily dosages of illegal heroin.
The Dutch have recently presented more detailed data on
what happens to people ejected from heroin treatment
because of the 12-month time restriction that was built
into their trial (as in NAOMI). In the Dutch heroin trial,
participants were considered to be "treatment responsive"
if they showed a 40% improvement in at least one
domain (e.g. drug use, arrests, health and mental status)
where they performed poorly at the beginning of the
study. Most did well. Of the group of 55 participants that
completed treatment during the first year of the experi-
mental period, 32 (58.2 %) were considered to be treat-
ment responsive. And, as is proposed for NAOMI, even
patients doing well were made to stop heroin treatment
and either go onto methadone, drug free programs, or
leave treatment altogether.
However, in the Dutch study a compassionate care provi-
sion was built in for safety – allowing the investigators to
re-admit individuals to heroin treatment if they reverted
to heroin use after the study. And most did, rather quickly.
Of the "successes", 84% deteriorated within two months
after heroin treatment was discontinued [35]. But most of
these were re-admitted to the program, and the Dutch are
now planning to institute the program as part of the avail-
able repertoire of treatment options.
The dilemma is clear – for many of these subjects (also
still patients) who have responded well to NAOMI, stop-
ping the provision of heroin will throw them back into a
world of pain and high risk as they, predictably, strive to
self-medicate with impure and unregulated illegal ver-
sions of heroin they can no longer receive safely under the
watchful eye of a NAOMI physician. This challenge con-
tinues as a growing crisis for NAOMI and its subjects as
more patients near the 12-month point.
Research ethics and public health
The most widely accepted document outlining ethical
standards for research at the international level is the Dec-
laration of Helsinki [36]. There is a crucial section, para-
graph 30, of the document that is pertinent to research on
heroin treatment for addiction. It reads:
"At the conclusion of the study, every patient entered into
the study should be assured of access to the best proven
prophylactic, diagnostic and therapeutic methods identi-
fied by the study"[37]
The main motive for this portion of the international
research guidelines is to prevent the sponsors of research
trials (government, university, hospital or private) and
physician collaborators from initiating research on sub-
jects who would otherwise be unable to access the treat-
ment offered in the research and then taking away the
treatment when the research schedule is complete [36].
Similarly, the International Code of Medical Ethics of the
World Medical Association (WMA) has recognized since
1949 that: "a doctor owes his patient complete loyalty and
all the resources of his science"[38].
The NAOMI has strictly fulfilled the ethical requirement
of the Declaration of Helsinki, particularly with regard to
the clarifying footnote added to paragraph 30 by the
World Medical Association in 2004:
"The WMA hereby reaffirms its position that it is necessary
during the study planning process to identify post-trial
access by study participants to prophylactic, diagnostic
and therapeutic procedures identified as beneficial in the
study or access to other appropriate care. Post-trial access
arrangements  or other care must be described in the
study protocol so the ethical review committee may con-
sider such arrangements during its review [emphasis
added]."[37]
The NAOMI definitely identified post-trial arrangements
and the ethical review boards of three institutions defi-
nitely considered these arrangements in their review.
However, the regulatory framework with respect to heroin
treatment for addiction left the research designers and eth-
ics reviewers in a difficult position of only being able to
offer, legally, already available traditional treatments that
had already repeatedly failed the patients in question. In
a difficult ethical position from the beginning, they dar-
ingly chose to carry onward because there was simply no
other option available to them if they were to stand any
chance to lay the groundwork for heroin treatment in
Canada. Without the clarifying footnote added to para-
graph 30 of the Declaration of Helsinki by the WMA in
2004, the NAOMI would not have been able to move for-
ward ethically.
Although this is commonly disregarded in the scrum of
international drug licensing differences and regulatory
variations – i.e. many well respected medications in longHarm Reduction Journal 2006, 3:16 http://www.harmreductionjournal.com/content/3/1/16
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term use in Europe are unavailable in the US, or items
available over the counter in one country, are available
only with prescriptions in another – in this case it is not
profits but human lives that are at issue. The scientific
facts about many key addiction initiatives are not really in
question. What is in dispute is how governments, in this
case the Government of Canada and its regulatory bodies,
should respond to the evidence base that science has by
now produced in some abundance, and the implications
of that evidence for practice in Canada.
Addiction treatment policies, like any medical or public
health practice, should be evidence-based. If not driven by
evidence they always have the potential to lose their moral
compass, especially if effective treatment that is available
is withheld. The infamous US Tuskegee Syphilis Study
provides a sad historical case of such treatment being
withheld, in this case penicillin, that was developed after
the trial began, but not made available to participants for
the sake of completing the scientific study. While it may
make some uncomfortable to relate this historical case to
the present situation, we present Tuskegee to make the
point that well-intentioned people who believe their
actions to be in the best interests of people and society
sometimes make unethical decisions that lead to social
and medical disasters.
But closer to home in Canada, we need only look back to
the quarantined lepers of Canada that were relegated to
isolated islands, D'Arcy Island and Bentinck Island, off the
coast of Vancouver Island to die without medical or social
support when their disease was amenable to medical care.
The lepers were given only rations and coffins and the
Government of British Columbia rebuffed assistance from
missionaries [39]. The medical establishment was aware
that leprosy was not acutely contagious but in spite of this
knowledge the panicked government officials exiled the
afflicted and left them to die without care. The ailing lep-
ers were expected to bury the dead until the banishment
stopped in 1957 when the last person with leprosy died.
Only lepers of Chinese ancestry were reduced in impor-
tance to receive this fate; the Euro-Canadian lepers from
all across Canada were sent to receive the kind help and
healthcare of the nuns of the Hospitallers of Saint Joseph
in New Brunswick [40].
A further example is seen in the establishment of reserves
or reservations for people of aboriginal ancestry, complete
with "Indian agents", that historically dictated when cattle
could be slaughtered, what crops were planted, where
children were schooled and in what language. In Canada,
it was not until 1960 that all people of aboriginal ancestry
were allowed to vote in federal elections and they were
not given this manifestation of personhood in Alberta
provincial elections until 1965. Individuals that believed
that they were helping aboriginal peoples in a relation-
ship of tutelage designed these social initiatives [41].
The Tuskegee Study, commenced in 1932, was originally
intended to take approximately one year, but continued
uninterrupted for forty years. This included a period of
some twenty-seven years after penicillin became the
accepted and widely obtainable cure for syphilis. Even
then, the discontinuation of the study was precipitated
not by medicine or public heath officials but by an article
by journalist Jean Heller published on the front page of
the Washington Evening Star (25 July 1972). Twenty-five
years later, on 16 May 1997, after hundreds of preventable
deaths in the original study cohort and allowing the par-
ticipants to unknowingly transmit the disease to their
partners and children, President Bill Clinton formally
apologized on behalf of all of America for the Tuskegee
study and the role that the US government had played
[42].
We do not mean to demonize research, policy makers or
researchers. It is unlikely that either the researchers or pol-
icy makers harbour any ill will towards those living with
active addictions living in the shadows of society. Simi-
larly, those who initiated the Tuskegee study did so as part
of a genuine dedication to improving quality of life for
African American people [43]. Nor was the study intended
to be ethnocentric. It was completed in partnership with
African American physicians, researchers and administra-
tors. The Tuskegee study of the effects of untreated syphilis
is different in one fundamental way from heroin treat-
ment for addiction element. At the time that Tuskegee
study was initiated, there were not efficacious treatments
for syphilis[44]. In contrast, in the case of heroin treat-
ment, it is a clinical intervention that has an established
scientific evidence base demonstrating its efficacy. The
continued government regulatory handling of a clinical
intervention, in this case heroin treatment, as a purely sci-
entific question thereby limiting access by patients who
would clearly benefit from it is, in our view, unethical and
increasingly politically and medically untenable.
One of the challenges to the development of best practices
in healthcare in Canada and elsewhere is the fact that con-
troversial innovations, such as genetic testing or addiction
treatment, are required to continue as research initiatives
for scientifically unwarranted periods of time. These
lengthened periods of time would not be acceptable in
other clinical trials. In addition to the genuine uncertain-
ties and questions that need to be answered before we can
proceed with something new and potentially hazardous
in medicine or public health, research is sometimes used
as a way to buy time. But while it is a way to buy time dur-
ing the period when the balance of public opinion about
addiction treatment evolves, it is ethically untenable, inHarm Reduction Journal 2006, 3:16 http://www.harmreductionjournal.com/content/3/1/16
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our view, to continue any treatment research (heroin
included) when the research questions have been sub-
stantially addressed and answered in other jurisdictions.
Consent revisited
As the NAOMI reaches the end of its first year, the first par-
ticipants are due for discharge from the trial – that is what
they agreed to when they entered the study in the first
place. But that consent may need to be reexamined in the
light of subsequent evidence. And the fact that heroin
addicts can only receive the treatment they desire for a
time-limited period that is dictated by research protocol,
without recourse to (for them) an effective treatment that
has proven itself in other valid studies, is (at best) ethi-
cally awkward with respect to informed consent. Modern
standards of informed consent have been developed most
substantially since the establishment of the Nuremberg
Code for experiments involving humans established in
1946 as a result of the legal prosecution of Nazi physicians
[45]. The expectation of informed consent for human sub-
jects is a complex issue when it comes to marginalized
individuals with active addictions whose access to the
analgesics to which they are addicted is only available
through research? It is, for example, disputable as to
whether Canadian citizens addicted to heroin that can
only receive medical grade heroin in Canada by partici-
pating in a rigorous scientific study are actually providing
informed consent without duress.
Harm reduction: evidence vs. politics
Consider the alternative to an evidence based medical and
public health response to the problem of refractory heroin
addiction. In the United States, incarceration is the most
widely available "treatment" response, universally "avail-
able" to drug users. While jail is widely touted as a step to
coming to terms with ones demons, all too often criminal-
ization converts a treatable drug problem into a social and
personal nightmare – a disastrous beginning point for
clinical intervention. While treatment compliance for
other chronic diseases varies, no one suggests that refrac-
tory diabetics or cigarette smokers or alcoholics should be
incarcerated "for their own good". Yet those living with
addictions often end up in the unwelcoming arms of the
criminal justice system.
Despite the mass of decisive evidence on the efficacy of
methadone in treating opiate addiction, methadone is
still treated as a pariah drug in many parts of the world.
Entire nations (e.g. Russia and India) today forbid its use
in addiction treatment and, in the US (where methadone
was first employed for addiction treatment) eight states
still outlaw its use. Even in the United States, though med-
ically approved, the clinical application of methadone is
so irrational (e.g. justifying systematic use of sub-clinical
doses) or downright mean-spirited and punitive, that,
despite its proven efficacy, many have grown to hate it.
Indeed much of the allure of the newly approved use of
buprenorphine is that it is "NOT methadone".
So important is the predominant demand reduction
approach in the United States that the Director of the
Office of National Drug Control Policy, Mr. John Walters,
has budget certification authority so that he can decertify
the budget of any federal department if it does not meet
drug control policy objectives. The Director is a cabinet
position that is appointed directly by the President. Under
this department, as part of the Executive Office of the Pres-
ident, there are 4 additional Senate confirmed positions
that all report to Mr. Walters. The Director reports directly
to the President of the United States and reviews all budg-
ets before they are finalized [29]. Accordingly, needle
exchange and distribution is widely accepted within the
US as scientifically irrefutable, yet almost universally dis-
regarded and denied funding by federal and many state
and municipal authorities.
To learn more about this first hand, one of us (DS) was
part of a group of international experts and practitioners
in substance abuse health programs who visited the US in
November of 2005, under the United States International
Visitors Program of the US Dept of State. On one leg of
that trip the group visited the Bloomberg School of Public
Health at John Hopkins University in Baltimore, where
several lecturers provided an overview of their research.
They emphasized the importance of science and, in partic-
ular, epidemiology in understanding addiction. When
asked about the science on needle exchange which US
Federal policies does not allow or support one of the lec-
turers resolutely stated to the group that they [he and his
fellow faculty present in the room] "know that needle
exchange is efficacious in saving lives but that it will never
receive public funding for political reasons".
Later, the group visited the National Institute on Drug
Abuse (NIDA), the research-funding arm of the Govern-
ment of the United States (whose billion-dollar budget
funds more than 85% of all the addiction research in the
world). When asked about needle distribution, the epide-
miologist and ethicist for NIDA promptly asserts that they
(presumably the senior scientists of NIDA) agree that nee-
dle exchange is efficacious in preventing HIV and HCV
infections "but we are not policy makers". Another senior
administrator and research psychologist for NIDA added
to the discussion by making the point that " drug users do
not have an organization or lobby so they have no impact
on policy". The approach of the US federal government to
needle distribution provides a current example of policy
makers ignoring scientific evidence for efficacious popula-
tion health intervention: with disastrous results.Harm Reduction Journal 2006, 3:16 http://www.harmreductionjournal.com/content/3/1/16
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Beyond randomized control trials
In light of the now massive body of scientific evidence
supporting the efficacy of heroin treatment with thou-
sands of patient years of experience in 5 national research
trials with the Swiss having prescribed heroin to several
thousand since the mid 1990's, a few hundred in the
Netherlands and Germany and over 75 years of UK gen-
eral medical practice–the PHS followed up its original
request to Health Canada with an appeal on 2 January
2006 asking once again that community physicians in
Vancouver's Downtown Eastside be permitted to pre-
scribe heroin through a clinic for people living with active
addicted to heroin but who have been unsuccessful with
other clinical interventions. This appeal was made to
Canadian health authorities on medical ethical grounds,
asking for an exemption under Section 56 of the Controlled
Drug and Substances Act (CDSA).
In a response written 14 February 2006, the Department
of Drug Strategy and Controlled Substances for Canada
stated that:
"While heroin prescription has shown some promising results in
Europe, sound evidence is needed to demonstrate its effective-
ness in the Canadian context before Health Canada can be in
a position to exempt heroin prescription for medical purposes..."
The letter points to the NAOMI study goal to determine
whether heroin treatment:
"...Will improve the health and quality of life of injection drug
users, reduce homelessness and decrease their interactions with
the criminal justice system."
Just because the patients are addicts and the treatment is
heroin, this issue for NAOMI does not exist in an ethical
vacuum. We believe there is a medical ethics legal argu-
ment to be made regarding standards of care and access to
effective health services for people with active addictions.
If the research in another sector were as clear, this treat-
ment protocol would by now be available e.g. if a new
drug for breast cancer or colon cancer were shown to be as
efficacious and effective as heroin has been shown to be,
then the clinical trial would generally be stopped and the
medical program, with ongoing scientific evaluation,
would commence immediately. If this were another drug
trial, say for treating hypertension, would there even have
been a statutory requirement for a study to be repeated in
Canada that had already established efficacy with thou-
sands of patients, and whose results had been published
in peer reviewed scientific literature elsewhere? While rep-
lication is an important part of the scientific method, does
a scientific fact have to be repeated in every single jurisdic-
tion? Would the prescription of a drug shown to be effec-
tive in treating breast cancer in Switzerland the UK and
The Netherlands have to be replicated in Canada before it
would be made available for Canadian patients? Extend-
ing this logic further, would the very same study also have
to be replicated in each of the individual provinces within
Canada to verify that the findings were applicable equally
in differing contexts of Newfoundland and Alberta?
We cannot choose to use evidence only when it suits pol-
icy objectives and ignore it when it contradicts them. Nor
can we discourage the collection of evidence base, using
scientific methods, for initiatives that are politically
unpopular such as supervised inhalation rooms. Once sci-
ence has demonstrated the evidence-based outcomes for
an efficacious medical treatment, then governments have
a medical legal obligation to citizens and prospective
patients to grant the legal authority to practitioners to pro-
vide them as part of the continuum of available treat-
ments. The Government of Canada through the
Department of Drug Strategy and Controlled Substances
at Health Canada needs to grant a medical exemption for
heroin treatment immediately so that patients who would
benefit from this medical treatment have access to it in
order to better live their lives.
The dilemma facing the NAOMI with respect to its sub-
jects at the end of the first phase of the trial has shown us
something very important: harm reduction is itself at a
crossroads. The potential for the medical prescription of
heroin is not alone at this busy, and dangerous, intersec-
tion of science, politics, ethics and morality as applied to
drug use and harm reduction. In a further letter to Health
Canada, the PHS requested permission to go beyond the
Supervised Injection Facility and operate a supervised
inhalation room – for people addicted to crack cocaine
and crystal methamphetamine in Vancouver's Downtown
Eastside. The agency already operates the Supervised
Injection Facility and perceived an Inhalation Room as a
natural extension of this harm reduction initiative. The
request was denied, stating that evidence was required to
prove that an inhalation facility could meet health needs.
The science, according to Health Canada, did not exist at
present and furthermore, an argument would have to be
made that such a facility would benefit from scientific
examination. So, then, the Director General of the Federal
Department of Drug Strategy and Controlled Substances
essentially asserts that science doesn't exist and such a
research question might not be worthy of scientific study
anyway. While relying on science to deny the request, the
Director makes a final fascinating assertion that an
exemption for a scientific study of a supervised inhalation
room would need one final requirement:Harm Reduction Journal 2006, 3:16 http://www.harmreductionjournal.com/content/3/1/16
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"The demonstrated support of key stakeholders and partners,
such as municipal and provincial health authorities and law
enforcement agencies."
(Correspondence from Health Canada dated 1 February
2006)
Here, the Health Canada representative makes it a condi-
tion that to obtain permission to initiate a scientific
research study one would require support from municipal
and state politicians along with that of state and federal
police. It is difficult to imagine another parallel where a
scientific research study, such as a clinical trial for a treat-
ment for colorectal cancer, would require the study's
authors or principal investigator to obtain a written
endorsement from the Chief of Police, Mayor and City
Council and Provincial Health Minister to proceed. It
appears that the scientific method is being used as part of
a government risk management strategy [46]. In the case
of institutional risk management, the perceived risk is to
the institution–a political risk–and the focus is on protect-
ing the government and not the patient. Indeed it could
be argued that the actual risk management issue for the
Government of Canada in the case of heroin treatment is
in failing to act when the scientific evidence demonstrat-
ing an efficacious treatment already exists.
Conclusion: a time for action
Our goal has been to make the case that when it comes to
addiction treatment, policy makers sometimes ignore sci-
ence and scientists sometimes ignore policy. This mutual
failure can be very costly. Science is but one arrow in the
quiver of policy change, but it is the responsibility of a
human being, acting ethically, to choose the arrow, and to
decide whether and when to release it from the bow and
in what direction to aim it. The NAOMI arrow is in the air,
but where will it land?
While medical research is certainly important for examin-
ing the efficacy and effectiveness of new treatments there
is more at stake in Canada's NAOMI than simply scientific
goals. Scientific results alone may not be sufficient to
affect practical policies, especially in the case of providing
a drug as demonized as heroin to addicted patient's, and
calling it treatment.
The Canadian heroin trial, like those that have taken place
in Switzerland, the Netherlands and Germany, addresses
a perplexing, expensive, and epidemiologically dangerous
dilemma: either severe addiction, intractable and destruc-
tive, is an illness, or, it is not. There are those who see great
threat in all drug maintenance approaches, believing that
some moral ideology they hold, rather than clinical out-
comes, should determine medical practice. This is a dan-
gerous idea and must be confronted head on. So the
conflict over heroin maintenance is also a great opportu-
nity, a chance to take an important step forward in the
medical responsibility and competency to engage the
world's growing problem with heroin injection, now driv-
ing the AIDS epidemics of dozens of countries and mil-
lions in population.
For much of the world, drug use and addiction are still
shrouded in a medieval cloak of moral disapproval. And
many nations' policies are still punitive and unforgiving
of professionals who are too accepting of drug use – wit-
ness the sharp attacks on Harm Reduction in the US and
in UN drug policy bodies [47]. With the pervasive and
easy access to potent drugs of all sorts growing daily (espe-
cially for the worlds poor and most disenfranchised pop-
ulations) and the paucity of access to effective treatment,
we have so far managed to turn addiction from a treatable
condition into the public health nightmare that has rele-
gated millions of people living with serious addictions to
poverty, prison and early death from preventable infec-
tions.
Basic non-judgmental harm reduction ideas, almost uni-
versally seen as supportive by drug users, their families,
and human rights advocates, are rejected by many author-
ities as "sending the wrong message" (vs. zero tolerance),
as "enabling" by hardliners. In addition, the notion of
"drug legalization", removing the drug issue from the
realm of criminal law altogether, is used as an accusation
akin to treason. And sadly, this is also true of addiction
treatment in much of medical practice. Various forms of
opiate maintenance treatment for serious and persistent
heroin addiction already have a better prognosis than
many other chronic medical or psychiatric conditions. Yet
clinical and scientific ignorance, therapeutic nihilism, and
medical neglect are still the norm in most of the world.
While genuflecting to the need for evidence base is part of
the new high mass for policy makers and addiction treat-
ment providers, in the case of addiction, the larger evi-
dence base of population data is often ignored. Across the
globe, most addiction treatment policy and practice have
only the most tenuous relation to scientific evidence –
witness the persistence of moralistic approaches based on
self abnegation, religious conversion, or tough love with
hardly any evidence to support them.
Addiction is a complex social issue that demands complex
social solutions. The modernistic employment of science
by the Canadian government to unearth incontrovertible
answers to addiction is misguided. Research, in contrast to
science, begins with recognition of the messiness of the
constellation of issues surrounding social issues like
addiction. Scientists, politicians and activists should notHarm Reduction Journal 2006, 3:16 http://www.harmreductionjournal.com/content/3/1/16
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"expect science to decrease the complex web of their lives"
[48].
An exit strategy
The focus for the transition plan regarding heroin pre-
scription under NAOMI should now shift from the
patients to the trial itself. The NAOMI researchers have
served Canada well and boldly carried their trial as far as
they can in difficult legal and regulatory circumstances
over which they have no control. The researchers have
shown strong leadership; and now it is time for policy
makers to meet them halfway and liberate them from the
dilemma of a study protocol that will force them to with-
hold treatment that they now know is feasible, well
accepted, safe, and effective for their patients.
The original grant dollars provided for the research should
be supplemented by the provincial and federal govern-
ments of Canada in order to expand the scope of the
NAOMI into a full scale addiction treatment program
with the present researchers overseeing ongoing evalua-
tion. The implementation of a full-scale heroin treatment
program could result in millions of dollars in cost savings
in public funds in Vancouver [49] and billions [50] in
Canada due to a reduction in hospital days, visits to emer-
gency departments and involvement in the criminal jus-
tice system, in addition to an increase in employability.
The trademark of high science, the randomized control
trial, will not unshackle policy makers and politicians
from the responsibility of making the difficult political
decisions that are steadfastly rooted in the social world.
Today, if ever, science itself does not meet its own "high"
standards for disconnection from society, and even virtu-
ous science is not really chaste – a pure science unfettered
by the vagaries of society. Witness the contemporary scan-
dals in pharmaceutical and stem cell research.
We know that the realms of science and the social are not
really separate spheres:
"The adjective 'social' has been used to weaken science's
claim to truth and certainty. And if you say that science is
socially constructed, that is considered wrong by scien-
tists. This tug-of-war between science and society, where
one gains what the other loses, is not longer the only game
in town. There is now an alternative. To the old slogan of
science–the more disconnected a discipline from society,
the better–now resonates a more realistic call for action:
The more connected a scientific discipline, the bet-
ter."[48]
All illness has a social component. The social dimension
is crucial for effective medical treatment and is clearly vis-
ible, if one stops to look, in the etiology of disease as well
as the quality and significance of its lived experience for
the patient, their family and the community. This is true
whether it is cancer, diabetes, schizophrenia, AIDS or
addiction.
In the case of heroin prescription, the significance of the
social context does not negate the unique place of the phy-
sician, who alone has the societal authority and responsi-
bility to prescribe this highly restricted drug to treat
disease and alleviate otherwise insurmountable pain. If
medical practitioners do not shoulder their responsibility
in this matter, then those with otherwise untreatable her-
oin addiction will be relegated to a world of unnecessary
pain, forced to live at the bottom rung of society. There,
they will be loathed for moral unevenness and imperfect
personalities and doomed, by force of circumstance, to
become a public menace and the target of law enforce-
ment.
The addiction physician understands very well that illness
is not only presented in the clinic; but instead originates
and manifests itself most often in the everyday world of
the addicted person and their family, a context where the
physician may have little real influence. Nowhere is the
social element of illness more unmistakable than in the
life world of people living with addiction, and their fami-
lies, where their social being is as much under threat by
the tarnishing effects of a disparaging society as is their
physical being by the hazards of unhealthy drugs and
unhygienic needles. The person living with addictions is
not alone in this position–there is a long history of ill-
nesses that were stigmatized right out of medical practice
but turned out to be quite treatable in the framework of
modern medicine such as leprosy, schizophrenia, and
today even AIDS. The only recourse is to thrust people liv-
ing with addictions back into the medical realm and to
support the practitioners who treat them humanistically.
This is not a new dilemma for medicine. In the Tate Gal-
lery hangs a 19th century canvas, simply titled "The Doc-
tor". It depicts a small child stricken with illness–the limp
body lays helplessly on a bed in a tiny cottage while a
compassionate country doctor watches over the child the
whole night until the early morning sun brings some res-
olution to the crisis and the child awakens restore to
health by the passage of time – with little the doctor can
do but be there for the child and the family.
The full breadth of the physician's work often ranges far
beyond the "science" of treatment and disease – often
inadequate to relieve suffering, and always at the wrong
end of deaths final victory. But the compassionate pres-
ence of the doctor is a crucial part of the patient's healing
journey, no matter how great the suffering and regardless
of the ultimate outcome.Harm Reduction Journal 2006, 3:16 http://www.harmreductionjournal.com/content/3/1/16
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In the lived experience that inspired the work by Fildes's
(1843–1927), the outcome was tragic – the child (the art-
ists own son) did not live to see the morning sun and died
Christmas morning 1877. But the kindness of the doctor
so moved the father that he painted the canvas as an hom-
age, not to medical science but to one doctors compassion
and spirit of solidarity [51,52]. That is the true art in med-
icine. It is time for heroin prescription to become part of
that art.
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